Boaz Weinstein’s abrdn Life Sciences Investors HQL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.56M Sell
78,095
-869,251
-92% -$15.4M 0.04% 194
2026
Q1
$15.4M Sell
947,346
-1,169,828
-55% -$19.6M 0.43% 56
2025
Q4
$35.5M Sell
2,117,174
-469,478
-18% -$7.89M 1.06% 18
2025
Q3
$40.1M Sell
2,586,652
-430,887
-14% -$5.9M 1.1% 19
2025
Q2
$38.7M Sell
3,017,539
-170,866
-5% -$2.11M 0.91% 24
2025
Q1
$40.5M Sell
3,188,405
-241,618
-7% -$3.27M 1.09% 19
2024
Q4
$45M Buy
3,430,023
+32
+0% +$462 1.05% 21
2024
Q3
$51.7M Hold
3,429,991
1.08% 25
2024
Q2
$48.6M Buy
3,429,991
+967,844
+39% +$13.1M 0.81% 25
2024
Q1
$33.6M Buy
2,462,147
+1,040,847
+73% +$14.4M 0.57% 30
2023
Q4
$19.1M Buy
1,421,300
+1,149,693
+423% +$14.1M 0.38% 71
2023
Q3
$3.39M Buy
271,607
+134,644
+98% +$1.77M 0.08% 174
2023
Q2
$1.85M Buy
+136,963
New +$1.89M 0.05% 232

Other funds holding HQL

Boaz Weinstein's HQL Position: Q2 2026 in Review

Boaz Weinstein reduced its abrdn Life Sciences Investors (HQL) stake by 92% in Q2 2026, selling an estimated $15.4M and leaving 78,095 shares worth $1.56M. The position accounts for 0.04% of the portfolio, ranked #194.

Boaz Weinstein first reported a position in HQL in Q2 2023 and has held it in 13 quarters since. The position peaked at $51.7M in Q3 2024. 83 funds tracked by Wall St. Rank hold HQL as of Q2 2026.

  • Boaz Weinstein held 78,095 shares of abrdn Life Sciences Investors worth $1.56M as of Q2 2026.
  • Boaz Weinstein sold 869,251 abrdn Life Sciences Investors shares in Q2 2026, an estimated $15.4M.
  • abrdn Life Sciences Investors made up 0.04% of Boaz Weinstein's portfolio in Q2 2026, its #194 holding.
  • Boaz Weinstein first reported a position in abrdn Life Sciences Investors in Q2 2023 and has held it in 13 quarters since.
  • Boaz Weinstein's abrdn Life Sciences Investors position peaked at $51.7M in Q3 2024.
  • 83 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.

Based on Saba Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.